CapsoVision (CV) Operating Leases (2024 - 2025)

CapsoVision (CV) reported Operating Leases of $477000.0 for Q4 2025, down 61.47% on a YoY basis from $1.2 million in Q4 2024, and down 51.23% sequentially from $978000.0 in Q3 2025.

CapsoVision (CV) Operating Leases (2024 - 2025) Analysis & Trends

CapsoVision (CV) has 2 years of Operating Leases data on file, last reported at $477000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 61.47% year-over-year to $477000.0; the trailing twelve-month figure through Dec 2025 stood at $477000.0 (down 61.47% YoY), and the FY2025 full-year result was $477000.0, down 61.47% from the prior year.
  • Operating Leases eased to $477000.0 in Q4 2025, from $978000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.2 million in Q4 2024 to a low of $477000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn
9 Smith & Nephew 25.80 Bn 25.22 Bn -
10 CapsoVision 162.07 Mn 151.95 Mn 1.95 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 477,000.00
Sep 30, 2025 978,000.00
Jun 30, 2025 687,000.00
Dec 31, 2024 1.24 Mn